Your browser doesn't support javascript.
loading
Plasma and CSF biomarkers in a memory clinic: Head-to-head comparison of phosphorylated tau immunoassays.
Ashton, Nicholas J; Puig-Pijoan, Albert; Milà-Alomà, Marta; Fernández-Lebrero, Aida; García-Escobar, Greta; González-Ortiz, Fernándo; Kac, Przemyslaw R; Brum, Wagner S; Benedet, Andréa L; Lantero-Rodriguez, Juan; Day, Theresa A; Vanbrabant, Jeroen; Stoops, Erik; Vanmechelen, Eugeen; Triana-Baltzer, Gallen; Moughadam, Setareh; Kolb, Hartmuth; Ortiz-Romero, Paula; Karikari, Thomas K; Minguillon, Carolina; Hernández Sánchez, Juan José; Navalpotro-Gómez, Irene; Grau-Rivera, Oriol; María Manero, Rosa; Puente-Periz, Víctor; de la Torre, Rafael; Roquer, Jaume; Dage, Jeff L; Zetterberg, Henrik; Blennow, Kaj; Suárez-Calvet, Marc.
Afiliación
  • Ashton NJ; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Sweden.
  • Puig-Pijoan A; Wallenberg Centre for Molecular and Translational Medicine, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Sweden.
  • Milà-Alomà M; King's College London, Institute of Psychiatry, Psychology & Neuroscience, Maurice Wohl Clinical Neuroscience Institute, London, UK.
  • Fernández-Lebrero A; NIHR Biomedical Research Centre for Mental Health & Biomedical Research Unit for Dementia at South London & Maudsley NHS Foundation, London, UK.
  • García-Escobar G; Cognitive Decline and Movement Disorders Unit, Neurology Department, Hospital del Mar, Barcelona, Spain.
  • González-Ortiz F; IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.
  • Kac PR; Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Brum WS; IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.
  • Benedet AL; Barcelonaßeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.
  • Lantero-Rodriguez J; Universitat Pompeu Fabra, Barcelona, Spain.
  • Day TA; Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES), Madrid, Spain.
  • Vanbrabant J; Cognitive Decline and Movement Disorders Unit, Neurology Department, Hospital del Mar, Barcelona, Spain.
  • Stoops E; IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.
  • Vanmechelen E; Barcelonaßeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.
  • Triana-Baltzer G; Cognitive Decline and Movement Disorders Unit, Neurology Department, Hospital del Mar, Barcelona, Spain.
  • Moughadam S; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Sweden.
  • Kolb H; Barcelonaßeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.
  • Ortiz-Romero P; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Sweden.
  • Karikari TK; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Sweden.
  • Minguillon C; Graduate Program in Biological Sciences: Biochemistry, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil.
  • Hernández Sánchez JJ; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Sweden.
  • Navalpotro-Gómez I; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Sweden.
  • Grau-Rivera O; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA.
  • María Manero R; ADx NeuroSciences, Technologiepark 94, Ghent, Belgium.
  • Puente-Periz V; ADx NeuroSciences, Technologiepark 94, Ghent, Belgium.
  • de la Torre R; ADx NeuroSciences, Technologiepark 94, Ghent, Belgium.
  • Roquer J; Neuroscience Biomarkers Janssen Research & Development La Jolla California, USA.
  • Dage JL; Neuroscience Biomarkers Janssen Research & Development La Jolla California, USA.
  • Zetterberg H; Neuroscience Biomarkers Janssen Research & Development La Jolla California, USA.
  • Blennow K; IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.
  • Suárez-Calvet M; Barcelonaßeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.
Alzheimers Dement ; 19(5): 1913-1924, 2023 05.
Article en En | MEDLINE | ID: mdl-36370462
INTRODUCTION: Direct comparisons of the main blood phosphorylated tau immunoassays in memory clinic populations are needed to understand possible differences. METHODS: In the BIODEGMAR study, 197 participants presenting with cognitive complaints were classified into an Alzheimer's disease (AD) or a non-AD cerebrospinal fluid (CSF) profile group, according to their amyloid beta 42/ phosphorylated tau (Aß42/p-tau) ratio. We performed a head-to-head comparison of nine plasma and nine CSF tau immunoassays and determined their accuracy to discriminate abnormal CSF Aß42/p-tau ratio. RESULTS: All studied plasma tau biomarkers were significantly higher in the AD CSF profile group compared to the non-AD CSF profile group and significantly discriminated abnormal CSF Aß42/p-tau ratio. For plasma p-tau biomarkers, the higher discrimination accuracy was shown by Janssen p-tau217 (r = 0.76; area under the curve [AUC] = 0.96), ADx p-tau181 (r = 0.73; AUC = 0.94), and Lilly p-tau217 (r = 0.73; AUC = 0.94). DISCUSSION: Several plasma p-tau biomarkers can be used in a specialized memory clinic as a stand-alone biomarker to detect biologically-defined AD. HIGHLIGHTS: Patients with an Alzheimer's disease cerebrospinal fluid (AD CSF) profile have higher plasma phosphorylated tau (p-tau) levels than the non-AD CSF profile group. All plasma p-tau biomarkers significantly discriminate patients with an AD CSF profile from the non-AD CSF profile group. Janssen p-tau217, ADx p-tau181, and Lilly p-tau217 in plasma show the highest accuracy to detect biologically defined AD. Janssen p-tau217, ADx p-tau181, Lilly p-tau217, Lilly p-tau181, and UGot p-tau231 in plasma show performances that are comparable to their CSF counterparts.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inmunoensayo / Proteínas tau / Enfermedad de Alzheimer / Disfunción Cognitiva Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Alzheimers Dement Año: 2023 Tipo del documento: Article País de afiliación: Suecia Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inmunoensayo / Proteínas tau / Enfermedad de Alzheimer / Disfunción Cognitiva Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Alzheimers Dement Año: 2023 Tipo del documento: Article País de afiliación: Suecia Pais de publicación: Estados Unidos